| ▹ | Episode 1: Early recognition and management of CaReMe Risk factors |
| ▹ | Episode 2: Comprehensive approach to early cardio-renal protection in T2DM: Beyond glycemic control |
| ▹ | Episode 3: ACS management: From acute to stable phase |
| ▹ | Episode 4: Early diagnosis of CKD: What should we know? |
| ▹ | Episode 5: Addressing concerns regarding comprehensive HF management: From guidelines to clinical practice |
| ▹ | Episode 6: New paradigm in CKD management: What have we learned from the SGLT2i class? |
| ▹ | Episode 1: Early recognition and management of CaReMe Risk factors |
| ▹ | Episode 2: Comprehensive approach to early cardio-renal protection in T2DM: Beyond glycemic control |
| ▹ | Episode 3: ACS management: From acute to stable phase |
| ▹ | Episode 4: Early diagnosis of CKD: What should we know? |
| ▹ | Episode 5: Addressing concerns regarding comprehensive HF management: From guidelines to clinical practice |
| ▹ | Episode 6: New paradigm in CKD management: What have we learned from the SGLT2i class? |
| ▹ | Episode 1: Early recognition and management of CaReMe Risk factors |
| ▹ | Episode 2: Comprehensive approach to early cardio-renal protection in T2DM: Beyond glycemic control |
| ▹ | Episode 3: ACS management: From acute to stable phase |
| ▹ | Episode 4: Early diagnosis of CKD: What should we know? |
| ▹ | Episode 5: Addressing concerns regarding comprehensive HF management: From guidelines to clinical practice |
| ▹ | Episode 6: New paradigm in CKD management: What have we learned from the SGLT2i class? |